Last updated: 10 April 2024 at 10:06pm EST

Jerzy Gumulka Net Worth




The estimated Net Worth of Jerzy Gumulka is at least $6.88 Тысяча dollars as of 1 February 2024. Jerzy Gumulka owns over 33,333 units of Cns Pharmaceuticals Inc stock worth over $6,881 and over the last 4 years Jerzy sold CNSP stock worth over $0.

Jerzy Gumulka CNSP stock SEC Form 4 insiders trading

Jerzy has made over 3 trades of the Cns Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Jerzy bought 33,333 units of CNSP stock worth $10,000 on 1 February 2024.

The largest trade Jerzy's ever made was buying 33,333 units of Cns Pharmaceuticals Inc stock on 1 February 2024 worth over $10,000. On average, Jerzy trades about 6,144 units every 42 days since 2020. As of 1 February 2024 Jerzy still owns at least 43,006 units of Cns Pharmaceuticals Inc stock.

You can see the complete history of Jerzy Gumulka stock trades at the bottom of the page.



What's Jerzy Gumulka's mailing address?

Jerzy's mailing address filed with the SEC is C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027.

Insiders trading at Cns Pharmaceuticals Inc

Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over $132,960 worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth $458,622 . The most active insiders traders include Christopher Downs, John M Climaco и Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of $6,051. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth $10,000.



What does Cns Pharmaceuticals Inc do?

cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.



What does Cns Pharmaceuticals Inc's logo look like?

Cns Pharmaceuticals Inc logo

Complete history of Jerzy Gumulka stock trades at Cns Pharmaceuticals Inc

Дата
#
Компания
инсайдер
Транзакция
Транзакция
Акции Цена за акцию Общая стоимость Акции после Источник
1 Feb 2024 Jerzy Gumulka
Директор
Купить 33,333 $0.30 $10,000
1 Feb 2024
43,006
19 Apr 2023 Jerzy Gumulka
Директор
Купить 2,500 $1.70 $4,250
19 Apr 2023
9,673
10 Apr 2023 Jerzy Gumulka
Директор
Купить 7,173 $0.74 $5,308
10 Apr 2023
7,173


Cns Pharmaceuticals Inc executives and stock owners

Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include: